Search | TVST | ARVO Journals

Showing 1 – 20 of 105

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Anatomy and Pathology/Oncology November 2024

Treatment of Conjunctival Melanoma Cell Lines With a Light-Activated Virus-Like Drug Conjugate Induces Immunogenic Cell Death

PDF

Sen Ma; Ruben V. Huis In't Veld; Elisabet de los Pinos; Ferry A. Ossendorp; Martine J. Jager
TAGS: cell lines, cytotoxicity, drug conjugates, immunogenic cell death, malignant melanoma of conjunctiva, viruses, tumor cells, hsp90 heat-shock proteins, polymyositis, prednimustine
Invest. Ophthalmol. Vis. Sci.. 2024; 65(13):3. https://doi.org/10.1167/iovs.65.13.3

Includes: Supplemental Content

Anatomy and Pathology/Oncology July 2024

Protein and mRNA Expression in Uveal Melanoma Cell Lines Are Related to GNA and BAP1 Mutation Status

PDF

Maria Chiara Gelmi; Arnoud H. de Ru; Peter A. van Veelen; Rayman T. N. Tjokrodirijo; Marc-Henri Stern; Alexandre Houy; Robert M. Verdijk; T. H. Khanh Vu; Bruce R. Ksander; Jolanda Vaarwater; Emine Kilic; Erwin Brosens; Martine J. Jager
TAGS: cell lines, intraocular melanoma, mutation, proteins, rna, messenger, bap1 gene, genes
Invest. Ophthalmol. Vis. Sci.. 2024; 65(8):37. https://doi.org/10.1167/iovs.65.8.37

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

Targeting HSP: Tr1 Cell-Mediated Immune Tolerance to HSP60 Attenuates Neurodegeneration in Glaucoma

Shuhong Jiang; Kin-Sang Cho; Eric F. Thee; Irvin Yi; Laila Carmen Prendergast; Ajay Ashok; Julie Chen; Li Pan; Maximilian Braun; Wai Lydia Tai; Sarita Pooranawattanakul; Kasim Gunes; Martine J Jager; Lucy Q Shen; Jianzhu Chen; Dongfeng Chen

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):936.

ARVO Annual Meeting Abstract June 2024

Characterizing Cytotoxic and Regulatory CD4+ T cells in Patients with Primary Open-Angle Glaucoma (POAG)

Laila Carmen Prendergast; Shuhong Jiang; Kin-Sang Cho; Grace Johnsen; Chhavi Saini; Maximilian Braun; Farris ElZaridi; Lucy Q Shen; Martine J Jager; Dongfeng Chen

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):574.

ARVO Annual Meeting Abstract June 2024

Mel285 and Mel290: the odd two out

Maria Chiara Gelmi; Peter A. Van Veelen; Rayman Tjokrodirijo; Marc-Henri Stern; Alexandre Houy; Erwin Brosens; Robert M. Verdijk; Jolanda Vaarwater; Emine Kilic; Martine J Jager

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2260.

ARVO Annual Meeting Abstract June 2024

Treatment of conjunctival melanoma cell lines with belzupacap sarotalocan (Bel-sar) induces Immunogenic cell death

Sen Ma; Ruben V Huis In’t Veld; Elisabet de los Pino; Ferry A Ossendorp; Martine J Jager

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4276.

Anatomy and Pathology/Oncology January 2024

Tumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model

PDF

Sen Ma; Ruben V. Huis in't Veld; Yang Hao; Zili Gu; Cadmus Rich; Maria Chiara Gelmi; Aat A. Mulder; Peter A. van Veelen; T. Khanh H. Vu; Thorbald van Hall; Ferry A. Ossendorp; Martine J. Jager
TAGS: melanoma, mice, neoplasms, pigmentation, cancer therapy, macrophage activation, cell lines
Invest. Ophthalmol. Vis. Sci.. 2024; 65(1):42. https://doi.org/10.1167/iovs.65.1.42

Includes: Supplemental Content

Review December 2023

PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma

PDF

Maria Chiara Gelmi; Gulçin Gezgin; Pieter A. van der Velden; Gregorius P. M. Luyten; Sietse J. Luk; Mirjam H. M. Heemskerk; Martine J. Jager
TAGS: cancer, cancer immunotherapy, cohort studies, intraocular melanoma, neoplasms, prognostic factors, t-lymphocytes, neoplasm metastasis, antigens, the cancer genome atlas project
Invest. Ophthalmol. Vis. Sci.. 2023; 64(15):36. https://doi.org/10.1167/iovs.64.15.36

Includes: Supplemental Content

Anatomy and Pathology/Oncology June 2023

In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity

PDF

Sen Ma; Ruben V. Huis In't Veld; Alexander Houy; Marc-Henri Stern; Cadmus Rich; Ferry A. Ossendorp; Martine J. Jager
TAGS: bap1 gene, cell lines, drug conjugates, hsp90 heat-shock proteins, intraocular melanoma, viruses, cytotoxicity, cell death
Invest. Ophthalmol. Vis. Sci.. 2023; 64(7):10. https://doi.org/10.1167/iovs.64.7.10

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2023

Dark tumour pigmentation in uveal melanoma predicts poor prognosis independently of size but not independently of chromosome 3 and 8q status

Maria Gelmi; Annemijn P.A. Wierenga; Wilma G.M. Kroes; Sjoerd van Duinen; Jessica Serena Karuntu; Marina Marinkovic; Jaco C. Bleeker; Gregorius P.M. Luyten; T.H. Khanh Vu; Robert M. Verdijk; Martine J Jager

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3273.

ARVO Annual Meeting Abstract June 2023

The anti-tumor efficiency of bel-sar (AU-011) treatment in a melanotic and an amelanotic (TYR knockout) B16F10 model in vitro and vivo

Sen Ma; Ruben V Huis In’t Veld; Cadmus Rich; Ferry A Ossendorp; Martine J Jager

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):876.

ARVO Annual Meeting Abstract June 2023

Metastatic spread from primary eye tumor after enucleation in a Uveal Melanoma orthotopic human to mouse xenograft model

Alice van den Broek; Nasrin Refaian; Cindy Hoppe; T.H. Khanh Vu; Martine J Jager; Bruce Ksander; Margarete Karg

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):895.

Anatomy and Pathology/Oncology December 2022

Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma

PDF

Kseniya Glinkina; Fariba Nemati; Amina F. A. S. Teunisse; Maria Chiara Gelmi; Vesnie Etienne; Muriel J. Kuipers; Samar Alsafadi; Martine J. Jager; Didier Decaudin; Aart G. Jochemsen
TAGS: foretinib, trabectedin, intraocular melanoma, cell lines
Invest. Ophthalmol. Vis. Sci.. 2022; 63(13):14. https://doi.org/10.1167/iovs.63.13.14

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2022

MITF: a progression marker in uveal melanoma

Maria Gelmi; Marina Marinkovic; T. H. Khanh Vu; Pieter A. van der Velden; Gregorius P. M. Luyten; Martine J Jager

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2353 – A0022.

ARVO Annual Meeting Abstract June 2022

Effect of surgical indication and disease severity on clinical outcomes and graft survival up to 10 years after Descemet Membrane Endothelial Keratoplasty

Indre Vasiliauskaite; Viridiana Kocaba; Korine van Dijk; Lamis Baydoun; Charlotte Lanser; Demi Lee; Martine J Jager; Gerrit RJ Melles; Silke Oellerich

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3640 – A0205.

ARVO Annual Meeting Abstract June 2021

Expression of immune checkpoint LAG3 is associated with high risk uveal melanoma

Zahra Souri; Gre Luyten; Martine J Jager

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):37.

ARVO Annual Meeting Abstract June 2021

Melanocytes, Inflammation and Responses in the Human Choroidal Microenvironment

Michele C Madigan; Chieh-Lin Wu; Martine J Jager; R. Max Conway; Riccardo Carlo Natoli; V. Adrian Cioanca

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2840.

Anatomy and Pathology/Oncology April 2021

Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin

PDF

Niels J. Brouwer; Eleni K. Konstantinou; Evangelos S. Gragoudas; Marina Marinkovic; Gregorius P. M. Luyten; Ivana K. Kim; Martine J. Jager; Demetrios G. Vavvas
TAGS: bap1 gene, cell growth, cell lines, genes, malignant melanoma of conjunctiva, mutation, neoplasms, uvea, verteporfin, proteins
Invest. Ophthalmol. Vis. Sci.. 2021; 62(4):3. https://doi.org/10.1167/iovs.62.4.3

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Targeting HSP: Immune Tolerance to HSP60 Attenuates Neurodegeneration in Glaucoma

Shuhong Jiang; Eric F. Thee; Elisa Arlotti; Kin-Sang Cho; Karen Chang; Li Pan; Jing Tang; Martine J Jager; Dongfeng Chen

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):649.

Anatomy and Pathology/Oncology March 2020

Prognostic Factors Five Years After Enucleation for Uveal Melanoma

PDF

Mehmet Dogrusöz; Niels J. Brouwer; Stefan J. R. de Geus; Long V. Ly; Stefan Böhringer; Sjoerd G. van Duinen; Wilma G. M. Kroes; Pieter A. van der Velden; Geert W. Haasnoot; Marina Marinkovic; Gregorius P. M. Luyten; Tero T. Kivelä; Martine J. Jager
TAGS: cellular enucleation, enucleation procedure, intraocular melanoma, neoplasms, prognostic factors, neoplasm metastasis, cohort studies
Invest. Ophthalmol. Vis. Sci.. 2020; 61(3):31. https://doi.org/10.1167/iovs.61.3.31

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Treatment of Conjunctival Melanoma Cell Lines With a Light-Activated Virus-Like Drug Conjugate Induces Immunogenic Cell Death

Protein and mRNA Expression in Uveal Melanoma Cell Lines Are Related to GNA and BAP1 Mutation Status

Targeting HSP: Tr1 Cell-Mediated Immune Tolerance to HSP60 Attenuates Neurodegeneration in Glaucoma

Characterizing Cytotoxic and Regulatory CD4+ T cells in Patients with Primary Open-Angle Glaucoma (POAG)

Mel285 and Mel290: the odd two out

Treatment of conjunctival melanoma cell lines with belzupacap sarotalocan (Bel-sar) induces Immunogenic cell death

Tumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model

PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma

In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity

Dark tumour pigmentation in uveal melanoma predicts poor prognosis independently of size but not independently of chromosome 3 and 8q status

The anti-tumor efficiency of bel-sar (AU-011) treatment in a melanotic and an amelanotic (TYR knockout) B16F10 model in vitro and vivo

Metastatic spread from primary eye tumor after enucleation in a Uveal Melanoma orthotopic human to mouse xenograft model

Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma

MITF: a progression marker in uveal melanoma

Effect of surgical indication and disease severity on clinical outcomes and graft survival up to 10 years after Descemet Membrane Endothelial Keratoplasty

Expression of immune checkpoint LAG3 is associated with high risk uveal melanoma

Melanocytes, Inflammation and Responses in the Human Choroidal Microenvironment

Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin

Targeting HSP: Immune Tolerance to HSP60 Attenuates Neurodegeneration in Glaucoma

Prognostic Factors Five Years After Enucleation for Uveal Melanoma

To View More...

You must be signed into an individual account to use this feature.